astrazeneca alexion presentation

Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Create your Watchlist to save your favorite quotes on Nasdaq.com. AstraZeneca’s $39 billion payment in cash and stock was valued at $175 per share of Alexion, and the stock of Alexion (ticker: ALXN) jumped 30% on Monday’s open, to $157. Alexion Overview - AstraZeneca Investor Presentation AstraZeneca Growth Is Back And The Progressive Dividend Will Follow AstraZeneca's Supply Issues Could Change The COVID-19 Game Board AstraZeneca’s $39 billion offer for Alexion will pay stockholders $175 per share — $54 more than the stock’s closing price Friday, for a 44 percent premium. Within Chemical Engineering you will: Be assigned a specific project alongside an experienced lead engineer. View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005200/en/, Alexion: You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Titlurile Alexion au închis, vineri, la aproximativ 121 de dolari pe acţiune. Each of Alexion and AstraZeneca may also file other relevant documents with the U.S. Securities and Exchange Commission (“SEC”) regarding the proposed transaction. AstraZeneca (NYSE: AZN) and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) have entered into a definitive agreement for AstraZeneca to acquire Alexion. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. The transaction is likely to complete during the third-quarter of 2021, following which, Alexion shareholders will own a 15% stake in the combined company. The presentation will be available at astrazeneca.com before the call takes place, ... Alexion, AstraZeneca and certain of their directors, executive officers and employees may be deemed participants in the solicitation of proxies from Alexion shareholders in connection with … Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Members of Alexion ‘s current senior management team will lead the future rare-disease activities. Alexion Pharmaceuticals, Inc. today announced recent commercial, clinical and financial progress and upcoming 2021 milestones, which will be detailed today in the company’ s presentation … By Ludwig Burger. Continued progress in advancing Phase 3 ULTOMIRIS trials in NMOSD and amyotrophic lateral sclerosis (ALS), which are now over 80 percent and 50 percent enrolled, respectively. Alexion finished 2019 with a 21% year-over-year jump in revenues to $4.991 billion, about one-fifth of the $24.384 billion in revenue reported in 2019 by AstraZeneca. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). This revenue target is expected to be driven by the continued growth of Alexion’s neurology franchise; expansion of ANDEXXA/ONDEXXYA® [coagulation factor Xa (recombinant), inactivated-zhzo] into new indications and geographies; sustainable paroxysmal nocturnal hemoglobinuria (PNH) and growing atypical hemolytic uremic syndrome (aHUS) and metabolics businesses; and initial revenue contributions from 10 potential new launches by 2023. Type a symbol or company name. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the proposed transaction and/or Alexion or AstraZeneca, AstraZeneca’s ability to successfully complete the proposed transaction and/or realize the expected benefits from the proposed transaction. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresse IP, Navigation et recherche lors de l’utilisation des sites Web et applications Verizon Media. Greater scientific presence in immunology by adding Alexion's innovative complement-technology platforms and strong pipeline Dedicated rare disease unit to be headquartered in Boston Geographical… What to Know. Participants in the solicitation AstraZeneca — whose Covid-19 vaccine efforts have stumbled in recent weeks — changed the subject by announcing it would buy Alexion … Amidst COVID-19 pressures throughout 2020, Alexion added more than 700 U.S. neurology patients over the course of the year, and now serves nearly 2,600 patients in the U.S. Vous pouvez modifier vos choix à tout moment dans vos paramètres de vie privée. https://www.astrazeneca.com/investor-relations.html, https://www.businesswire.com/news/home/20210112005200/en/, Do Not Sell My Personal Information (CA Residents Only). I am very proud of the hard work of all our teams who continue to be so dedicated to serving patients across the globe,” said Ludwig Hantson, Ph.D., Chief Executive Officer at Alexion. Investors and security holders will be able to obtain free copies of the registration statement and proxy statement/prospectus (if and when available) and other documents containing important information about Alexion, AstraZeneca and the proposed transaction, once such documents are filed with the SEC through the website maintained by the SEC at http://www.sec.gov. Presentation at the 39th Annual J.P. Morgan Healthcare Conference. Sâmbătă, AstraZeneca a anunţat că acţionarii Alexion vor primi 60 de dolari în numerar şi 2,1243 de acţiuni AstraZeneca tranzacţionate în SUA pentru fiecare titlu Alexion, ceea ce implică un preţ total de 175 de dolari pe acţiune. “Over the course of past year, Alexion has continued to execute on its value-creation strategy and delivered on the potential of its robust portfolio and clinical pipeline, giving us great momentum as we enter 2021. UK: +44 203 481 5237 Sweden: +46 8 5052 0017 US: +1 301 715 8592. On December 12, 2020, AstraZeneca and Alexion announced that the companies entered into a definitive agreement for AstraZeneca to acquire Alexion, in which Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) for each Alexion share. Information about AstraZeneca’s directors and executive officers is available in AstraZeneca’s Form 20-F filed with the SEC on March 3, 2020, and other documents subsequently filed by AstraZeneca with the SEC. Important risk factors could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to, the risks that: a condition to the closing the proposed acquisition may not be satisfied; a regulatory approval that may be required for the proposed acquisition is delayed, is not obtained or is obtained subject to conditions that are not anticipated; AstraZeneca is unable to achieve the synergies and value creation contemplated by the proposed acquisition; AstraZeneca is unable to promptly and effectively integrate Alexion’s businesses; management’s time and attention is diverted on transaction related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of the combined company declines following the proposed acquisition; legal proceedings are instituted against Alexion, AstraZeneca or the combined company; Alexion, AstraZeneca or the combined company is unable to retain key personnel; and the announcement or the consummation of the proposed acquisition has a negative effect on the market price of the capital stock of Alexion or AstraZeneca or on Alexion’s or AstraZeneca’s operating results. You are cautioned not to rely on Alexion’s and AstraZeneca’s forward-looking statements. Based on AstraZeneca's reference average ADR price of $54.14 at the time of the announcement, this implied total consideration to Alexion shareholders of $39 billion or $175 per share. AstraZeneca will pay $60 in cash and 2.1243 AstraZeneca American Depositary Shares for each Alexion share held. 1. AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced recent commercial, clinical and financial progress and upcoming 2021 milestones, which will be detailed today in the company’s presentation at the 39th Annual J.P. Morgan Healthcare Conference. Type a symbol or company name. The structure of the paying will be in both cash and shares. Executive Director, Corporate Communications When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Nick Stone - IR, AstraZeneca. AstraZeneca and Alexion Combination. Additional Information and Where to Find It. Over the course of 2020, the company has built upon, and expanded its expertise in terminal complement inhibition and other areas. - Continued advancement of pipeline, including initiation of three Phase 3 development programs and two novel IND filings in Q4 2020 -, - Expects to exceed the high end of 2020 revenue guidance, given at Q3 2020 results, of $5.9-$5.95 billion -, - Recently announced acquisition agreement will enhance AstraZeneca’s presence in immunology and provides opportunity to expand on Alexion's innovative complement-technology platforms -. This document is not a substitute for the proxy statement/prospectus or registration statement or any other document that Alexion or AstraZeneca may file with the SEC. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of Alexion stockholders in connection with the proposed mergers, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the proxy statement/prospectus when it is filed with the SEC. Subject to receipt of regulatory clearances and the approval by AstraZeneca and Alexion shareholders, the companies expect the acquisition to close in the third quarter of 2021. In connection with the proposed transaction, AstraZeneca PLC (“AstraZeneca”) intends to file with the SEC a registration statement on Form F-4 that will include a proxy statement of Alexion and that also constitutes a prospectus of AstraZeneca. AstraZeneca will pay $175 per share of Alexion; this represents a 45% control premium to Alexion shareholders based on the closing price of Alexion on the 11 th December 2020. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. Subject to completion of the review of the financial results, the company expects to exceed the high end of 2020 full-year revenue guidance of $5.9 to $5.95 billion that it provided in its 2020 third quarter results. These forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. Alexion shareholders will … As usual, the presentation was posted to astrazeneca.com, and we have also sent it to people and our distribution list. AstraZeneca (), one of the frontrunners in the drugs industry’s search for a COVID-19 vaccine, announced on Saturday that it will acquire US drugmaker Alexion for $39bn (£29.5bn).Under the terms of the transaction, the FTSE 100 firm said that Alexion shareholders will get $60 in cash and about 2.1 from AstraZeneca’s US-listed shares for each Alexion share they own. AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. The presentation will be available at astrazeneca.com before the call takes place, ... Alexion, AstraZeneca and certain of their directors, executive officers and employees may be deemed participants in the solicitation of proxies from Alexion shareholders in connection with the proposed transaction. This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Pascal Soriot - CEO, AstraZeneca. This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Brennan has served on the Alexion board of directors since 2014. Additional information concerning these risks, uncertainties and assumptions can be found in Alexion’s and AstraZeneca’s respective filings with the SEC, including the risk factors discussed in Alexion’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q, in AstraZeneca’s most recent Annual Report on Form 20-F and in each company’s future filings with the SEC. AstraZeneca PLC (NASDAQ:AZN) AstraZeneca to acquire Alexion Conference Call December 12, 2020 9:00 AM ET. Alexion, AstraZeneca, their respective directors and certain of their executive officers and other employees may be deemed to be participants in the solicitation of proxies from Alexion’s stockholders in connection with the proposed transaction. These symbols will be available throughout the site during your session. Yale-New Haven Hospital physician Leonard Bell led the launch of Alexion in 1992, with Bell a disease pathology professor at Yale University where he received his own medical degree. Welcome to the full year 2020 conference call and our webcast for investors and analysts. The proposed combination will broaden Alexion’s footprint, enabling the company to help more patients, pursue innovative science in new areas and expand its therapies in additional geographies. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Alexion (ticker: ALXN) shareholders will receive $60 in cash plus 2.1243 AstraZeneca American depositary receipts for each share they own, according to a … Chris Stevo, 857-338-9309 Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Please turn to Slide 2. Statements in this communication regarding Alexion, AstraZeneca and the combined company that are forward-looking, including anticipated revenue for Alexion for fiscal year 2020, future revenue for Alexion (including in 2025), 10 potential new launches by 2023, projections as to the anticipated benefits of the proposed transaction, the impact of the proposed transaction on Alexion’s and AstraZeneca’s businesses and future financial and operating results, the amount and timing of synergies from the proposed transaction, the terms and scope of the expected financing for the proposed transaction, the aggregate amount of indebtedness of the combined company following the closing of the proposed transaction, are based on management’s estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond Alexion’s and AstraZeneca’s control. “For almost 30 years, Alexion has been committed to transforming the lives of those impacted by rare diseases and devastating conditions, and the company remains focused on advancing its innovative therapies and pipeline to drive value for patients and shareholders once we are part of AstraZeneca.”, Robust Portfolio Positions Alexion for Growth. In addition, the transaction delivers significant value for Alexion’s shareholders, who will have an important stake in the combined company’s future results. Alexion shareholders will receive $60 in cash plus 2.12 new AstraZeneca shares (priced at $54.14). Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. The company has the ambition to deliver double-digit topline growth through 2025, targeting $9 to $10 billion in global revenue. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Statements in this communication regarding Alexion, AstraZeneca and the combined company that … Guidance at CER and excludes COVID-19 Vaccine AstraZeneca and Alexion. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, what impact they will have on the results of operations, financial condition or cash flows of Alexion or AstraZeneca. The acquisition has the potential to advance the shared science-led mission of both companies to leverage complementary approaches to developing life-changing medicines. Media Management and employees. Copy and paste multiple symbols separated by spaces. © 2021, Nasdaq, Inc. All Rights Reserved. Copies of the documents filed with the SEC by AstraZeneca will be available free of charge on AstraZeneca’s website at https://www.astrazeneca.com/investor-relations.html or by contacting AstraZeneca’s Investor Relations department by email at global-mediateam@astrazeneca.com. Dosing is underway in Phase 3 trials of ULTOMIRIS in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), ALXN2060 (AG10) in ATTR cardiomyopathy in, The Clinical Trial Approval (CTA) scheme for ALXN1820 (bi-specific anti-properdin mini-body) and the Investigational New Drug (IND) application for ALXN1850 (next generation asfotase alfa) have been accepted, in. Pour autoriser Verizon Media et nos partenaires à traiter vos données personnelles, sélectionnez 'J'accepte' ou 'Gérer les paramètres' pour obtenir plus d’informations et pour gérer vos choix. Alexion remains confident in the sustainability and growth potential of its innovative pipeline. AstraZeneca Q4 2020 Earnings ... statements disclaimer in the slide deck that accompanies this presentation and webcast. On December 12, 2020, AstraZeneca and Alexion announced that the companies entered into a definitive agreement for AstraZeneca to acquire Alexion, in which Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) for each Alexion share. Neither Alexion nor AstraZeneca assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date. ... harbor statements including Alexion-related balance on Slide 3. This press release and further information about Alexion can be found at: www.alexion.com. Image source: AstraZeneca presentation, Dec. 12, 2020. Company Participants. Information about Alexion’s directors and executive officers is available in Alexion’s proxy statement for its 2020 annual meeting of stockholders, which was filed with the SEC on March 26, 2020, Alexion’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which was filed with the SEC on February 4, 2020, and other documents subsequently filed by Alexion with the SEC. Investors Nos partenaires et nous-mêmes stockerons et/ou utiliserons des informations concernant votre appareil, par l’intermédiaire de cookies et de technologies similaires, afin d’afficher des annonces et des contenus personnalisés, de mesurer les audiences et les contenus, d’obtenir des informations sur les audiences et à des fins de développement de produit. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. Copies of the documents filed with the SEC by Alexion will be available free of charge on Alexion’s website at http://www.alexion.com or by contacting Alexion’s Investor Relations Department by email at InvestorRelations@alexion.com. The company remains on track to reach its stated long-term ambition to treat roughly 7,500 people with generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) in the United States by year end 2025. Découvrez comment nous utilisons vos informations dans notre Politique relative à la vie privée et notre Politique relative aux cookies. Presentation at the 39th Annual J.P. Morgan Healthcare Conference. Webinar ID: 995 4603 8702 Password: 12121220 Alexion said it expects to file the Form 10-Q by the end of December or in early January, although no specific timeframe was given. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Archived versions of the remarks will also be available through the company’s website for a limited time following the conferences. Develop a range of transferable attributes including communication and presentation skills. Total revenue for Tagrisso, Imfinzi, Farxiga, Lynparza, Calquence, Fasenra, Enhertu, Lokelma, Koselugo, Brilinta, roxadustat, Breztri and Bevespi 2. Following the job changes, Alexion tapped David Brennan, the former CEO of AstraZeneca PLC, as the company’s interim chief executive. These factors include, among other things, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions and the ultimate outcome of any litigation matter. AstraZeneca To Pay $39 Billion For Alexion. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond Alexion’s and AstraZeneca’s control. Have the opportunity to learn about the application of engineering in drug development, and lead your own 10-week project. These are the usual Safe Harbor statements, including an Alexion-related balance on Slide 3. The definitive proxy statement/prospectus (if and when available) will be mailed to stockholders of Alexion. The following presentation was made available by AstraZeneca PLC on its website on February 11, 2021. Yahoo fait partie de Verizon Media. – Barron’s Barron's 2 months AstraZeneca to Buy Alexion Pharmaceuticals for $39 Billion. Alexion will webcast its corporate presentation, given by Aradhana Sarin, M.D., Chief Financial Officer, at the 39th Annual J.P. Morgan Healthcare Conference today, Tuesday, January 12, 2021 at 7:30 a.m. Eastern Time. Audio webcasts of the presentations will be available live at: http://ir.alexion.com. presentation does not constitute or form part of, and should not be construed as, any offer, invitation or recommendation to purchase, sell or subscribe for any ... from AstraZeneca or Alexion as described in the paragraphs below. What to Know. Megan Goulart, 857-338-8634 2 months AstraZeneca-Alexion Acquisition Question Reddit 2 months AstraZeneca’s Alexion Splurge Could Attract a Crowd The Wall Street Journal 2 months AstraZeneca to Buy Alexion Pharmaceuticals for $39 Billion. Select pipeline updates, since third quarter results were reported in October 2020, regarding promising individual programs and broader platform opportunities include: Financial Execution Supports Strong Performance. Completion of enrollment in the Phase 3 trial of ULTOMIRIS in gMG, with top-line data expected in the second half of 2021. Please join 10-15 minutes prior to the scheduled start time. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. Head of Investor Relations. Despite the effects of COVID-19, Alexion continued to support its commitment to disciplined financial management and strong commercial performance, demonstrating the dedication and resilience of our colleagues around the globe. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support BOSTON--(BUSINESS WIRE)-- Alexion continues to expand into additional therapeutic areas, with a pipeline of more than 20 development programs across seven rare disease franchises.
astrazeneca alexion presentation 2021